Google
Trusted Resources: News & Events
Latest announcements and gatherings
MARAC Advisory Statement: Update About COVID-19 Vaccines
September 24, 2021 — News about COVID-19 continues to move quickly as we weather the pandemic. The Sickle Cell Disease Association of America’s Medical and Research Advisory Committee provides the following updates on vaccination recommendations:
1. Individuals with SCD are now eligible for the third dose of the COVID-19 vaccine. The CDC recommends that people who are immunocompromised or have medical conditions with poor antibody production receive vaccine boosters. One of the eligible conditions is asplenia (no spleen function). Because of the relationship between asplenia and SCD, sickle cell patients are eligible to receive a third dose of the vaccine if they have already received the first two doses.
2. If you have not had the first dose of the vaccine, please do so as soon as possible. Nearly everybody is eligible to receive their first shot. Only children under age 12 or individuals with known allergies to the vaccine ingredients are ineligible. Thousands of individuals with SCD have now had the COVID-19 vaccine. Like the public, many had some side effects that went away after three days. Only a tiny number of individuals experienced sickle cell pain after their shot. A COVID-19 infection poses a great risk for people with SCD. The vaccine is a safe way to reduce that risk. To find a vaccine location near you, visit www.vaccines.gov.
+myBinderRelated Content
-
The ELM ProjectThe mission of The ELM Project is to enh...
-
The Nazhi Thee Baker Angel Foundation Inc.The Nazhi Thee Baker Angel Foundation In...
-
Tina Kay HughesRetired at the age of 34 because of Sick...
-
Leigh Ann Wilson, LCSWLeigh Ann Wilson is a licensed clinical ...
-
Toy Drive & Holiday CelebrationIn efforts to assist in spreading holida...
-
Newborn screening for sickle cell disease in Europe: Recommendations from a Pan-European Consensus ConferenceSickle Cell Disease (SCD) is an increasi...
-
Point-of-care screening for sickle cell disease in low-resource settings: A multi-center evaluation of HemoTypeSC, a...Sickle cell disease (SCD) is a common, l...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.